Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition.
Koch MS, Czemmel S, Lennartz F, Beyeler S, Rajaraman S, Przystal JM, Govindarajan P, Canjuga D, Neumann M, Rizzu P, Zwirner S, Hoetker MS, Zender L, Walter B, Tatagiba M, Raineteau O, Heutink P, Nahnsen S, Tabatabai G. Koch MS, et al. Among authors: tatagiba m. Neurooncol Adv. 2020 Sep 10;2(1):vdaa115. doi: 10.1093/noajnl/vdaa115. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33134924 Free PMC article.
Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma.
Przystal JM, Becker H, Canjuga D, Tsiami F, Anderle N, Keller AL, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G. Przystal JM, et al. Among authors: tatagiba m. Cancers (Basel). 2021 May 15;13(10):2400. doi: 10.3390/cancers13102400. Cancers (Basel). 2021. PMID: 34063518 Free PMC article.
Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.
Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G. Rajaraman S, et al. Among authors: tatagiba m. Mol Ther Oncolytics. 2018 Dec 31;12:147-161. doi: 10.1016/j.omto.2018.12.010. eCollection 2019 Mar 29. Mol Ther Oncolytics. 2018. PMID: 30775418 Free PMC article.
Corticosteroid-responsive aseptic meningitis during regorafenib treatment.
Gepfner-Tuma I, Hirsch S, Schittenhelm J, Tzaridis T, Ziemann U, Tatagiba M, Herrlinger U, Tabatabai G. Gepfner-Tuma I, et al. Among authors: tatagiba m. Neurooncol Pract. 2019 Dec;6(6):508-509. doi: 10.1093/nop/npz030. Epub 2019 Jul 18. Neurooncol Pract. 2019. PMID: 32257278 Free PMC article. No abstract available.
H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M; International Consortium on Meningiomas; Schittenhelm J, Tabatabai G. Behling F, et al. Among authors: tatagiba m. Neuro Oncol. 2021 Aug 2;23(8):1273-1281. doi: 10.1093/neuonc/noaa303. Neuro Oncol. 2021. PMID: 33367841 Free PMC article.
Increased proliferation is associated with CNS invasion in meningiomas.
Behling F, Fodi C, Wang S, Hempel JM, Hoffmann E, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J, Skardelly M. Behling F, et al. Among authors: tatagiba m. J Neurooncol. 2021 Dec;155(3):247-254. doi: 10.1007/s11060-021-03892-7. Epub 2021 Nov 20. J Neurooncol. 2021. PMID: 34800210 Free PMC article.
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A; International Consortium on Meningiomas; Zadeh G, Aldape KD. Nassiri F, et al. Among authors: tatagiba m. Neuro Oncol. 2019 Jul 11;21(7):901-910. doi: 10.1093/neuonc/noz061. Neuro Oncol. 2019. PMID: 31158293 Free PMC article.
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G. Skardelly M, et al. Among authors: tatagiba ms. Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30. Oncologist. 2017. PMID: 28360216 Free PMC article.
491 results